IFN-γ cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient

Clinical Immunology

Volumn 138, Issue 3, 2011, Pages 282-290

  de Wetering, Diederik van ^a   van Wengen, Annelies ^a   Savage, Nigel D L ^a   van de Vosse, Esther ^a   van Dissel, Jaap T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

IFN ; IFN ; IFN R1 deficiency; Mendelian susceptibility to mycobacterial disease; Mycobacteria; Treatment

Indexed keywords

GAMMA INTERFERON RECEPTOR 1; IMMUKINE; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALPHA INTERFERON; CD14 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; INTERLEUKIN DERIVATIVE; STAT1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MONOCYTE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MONONUCLEAR CELL; MYCOBACTERIOSIS;

ANTIGENS, CD14; CELLS, CULTURED; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MACROPHAGES; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM SMEGMATIS; RECEPTORS, INTERFERON; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79851514164     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.12.005     Document Type: Article

References (36)

1. van de Vosse E., Hoeve M.A., Ottenhoff T.H. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004, 4:739-749.
2. Holland S.M. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000, 2:1579-1590.
3. Dorman S.E., Picard C., Lammas D., et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004, 364:2113-2121.
4. Ward C.M., Jyonouchi H., Kotenko S.V., Smirnov S.V., Patel R., Aguila H., McSherry G., Dashefsky B., Holland S.M. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur J Pediatr 2007, 166:981-985.
5. Rapkiewicz A.V., Patel S.Y., Holland S.M., Kleiner D.E. Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-gamma receptor 2 deficiency. Virchows Arch 2007, 451:95-100.
6. David M., Larner A.C. Activation of transcription factors by interferon-alpha in a cell-free system. Science 1992, 257:813-815.
7. Fu X.Y., Schindler C., Improta T., Aebersold R., Darnell J.E. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992, 89:7840-7843.
8. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
9. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
10. Noordzij J.G., Hartwig N.G., Verreck F.A., De Bruin-Versteeg S., de Boer T., van Dissel J.T., De Groot R., Ottenhoff T.H., Van Dongen J.J. Two patients with complete defects in interferon gamma receptor-dependent signaling. J Clin Immunol 2007, 27:490-496.
11. Verreck F.A., de Boer T., Langenberg D.M., Hoeve M.A., Kramer M., Vaisberg E., Kastelein R., Kolk A., de Waal-Malefyt R., Ottenhoff T.H. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004, 101:4560-4565.
12. Kuijl C., Savage N.D., Marsman M., et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 2007, 450:725-730.
13. Platanias L.C., Fish E.N. Signaling pathways activated by Interferons. Exp Hematol 1999, 27:1583-1592.
14. Ioan-Facsinay A., de Kimpe S.J., Hellwig S.M., et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002, 16:391-402.
15. Vey E., Zhang J.H., Dayer J.M. IFN-gamma and 1, 25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol 1992, 149:2040-2046.
16. Shang X.Z., Issekutz A.C. Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol 1998, 28:1970-1979.
17. van de Stolpe A., van der Saag P.T. Intercellular adhesion molecule-1. J Mol Med 1996, 74:13-33.
18. Ottenhoff T.H., Verreck F.A., Hoeve M.A., van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis 2005, 85:53-64.
19. Jacobs M., Togbe D., Fremond C., et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 2007, 9:623-628.
20. van de Wetering D., de Paus R.A., Van Dissel J.T., van de Vosse E. Salmonella induced IL-23 and IL-1β allow for IL-12 production by monocytes and Mφ1 through induction of IFN-γ in CD56 NK/NK-like T cells. PLoS ONE 2009, 4:e8396.
21. Hayes M.P., Wang J., Norcross M.A. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995, 86:646-650.
22. Chomarat P., Rissoan M.C., Banchereau J., Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993, 177:523-527.
23. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., Biron C.A. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000, 1:70-76.
24. Cousens L.P., Orange J.S., Su H.C., Biron C.A. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. Proc Natl Acad Sci USA 1997, 94:634-639.
25. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., Barry C.E., Freedman V.H., Kaplan G. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci USA 2001, 98:5752-5757.
26. Manca C., Tsenova L., Freeman S., Barczak A.K., Tovey M., Murray P.J., Barry C., Kaplan G. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005, 25:694-701.
27. Khader S.A., Bell G.K., Pearl J.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
28. Bouchonnet F., Boechat N., Bonay M., Hance A.J. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun 2002, 70:3020-3025.
29. Habermann T.M., Andersen J.W., Cassileth P.A., Bennett J.M., Oken M.M. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992, 80:466-471.
30. Toren A., Ackerstein A., Gazit D., Or R., Raveh D., Kupolovicz U., Engelhard D., Nagler A. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy. Bone Marrow Transplant 1996, 18:209-210.
31. Sleijfer S., Bannink M., Van Gool A.R., Kruit W.H., Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 2005, 27:423-431.
32. Giosue S., Casarini M., Alemanno L., Galluccio G., Mattia P., Pedicelli G., Rebek L., Bisetti A., Ameglio F. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998, 158:1156-1162.
33. Palmero D., Eiguchi K., Rendo P., Castro Z.L., Abbate E., Gonzalez Montaner L.J. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999, 3:214-218.
34. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005, 44:714-720.
35. Hikawa N., Ishikawa Y., Takenaka T. Interleukin-12 p40-homodimer production in sensory dorsal root ganglion neurons. Neuroscience 2004, 129:75-83.
36. Walter M.J., Kajiwara N., Karanja P., Castro M., Holtzman M.J. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med 2001, 193:339-351.